FDA backs NCL’s medication adherence campaign
SILVER SPRING, Md. — The Food and Drug Administration is putting its weight behind a campaign by the National Consumers League to combat poor medication adherence.
According to an entry in The Federal Register, the agency is awarding a $40,000 grant for the year to the NCL, as well as the possibility of additional $40,000 grants next year and the year after, to fund the organization’s national campaign to bring together retail pharmacy chains, healthcare professionals, insurance companies, drug companies, health information technology companies, businesses, labor unions, government agencies and others in order to target patients with chronic disease states and healthcare practitioners.
In addition to putting patients at risk, poor medication adherence is estimated to cost the economy $290 billion per year, according to the entry.
NACDS presents RxImpact ‘U’ Advocacy Award
WASHINGTON — Advocacy on behalf of pharmacy at the state level has won recognition from the National Association of Chain Drug Stores for a pharmacy school in West Virginia.
The NACDS said it gave its RxImpact “U” Advocacy Award to students Katrina Thompson and John Hudson from the University of Charleston School of Pharmacy for their leadership in organizing student participation in a Pharmacist’s Legislative Day at the West Virginia State Capitol.
“NACDS RxImpact ‘U’ was developed to engage the next generation of pharmacy — pharmacy school students — in grassroots advocacy,” NACDS president and CEO Steve Anderson said. “Katrina and John have demonstrated a commitment to telling pharmacy’s story, and serve as fine examples for other advocates participating in NACDS RxImpact Day on Capitol Hill.”
Under PEPFAR, Matrix Labs gets OK to sell zidovudine tablets
PITTSBURGH — A subsidiary of Mylan has won approval to sell a generic drug for HIV and AIDS in developing countries under the President’s Emergency Plan for AIDS Relief.
Mylan announced Thursday that Matrix Labs won Food and Drug Administration approval for zidovudine tablets in the 100-mg strength. The drug is a generic version of ViiV Healthcare’s Retrovir, an antiretroviral sold as a water-dispersible tablet. The drug is designed to treat HIV and AIDS in children and prevent transmission of the virus from pregnant mothers to their children.
“According to PEPFAR, prevention of mother-to-child transmission of HIV is extraordinarily effective,” Mylan president Heather Bresch stated. “Without PMTCT, 25% to 40% of babies of HIV-positive mothers will be born infected; with PMTCT, that number drops to below 5%.”